证券代码：300676 证券简称：华大基因 公告编号：2025-049 深圳华大基因股份有限公司 股东询价转让计划书 股东深圳华大基因科技有限公司保证向深圳华大基因股份有限公司提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称中金公司）组织实施华大基 因首发前股东询价转让（以下简称本次询价转让）。截至 2025 年 9 月 12 日，出让 方所持首发前股份的数量、占总股本比例情况如下： | 拟参与转让股东的名称 | 持股数量（股） | 持股比例 | | --- | --- | --- | | 深圳华大基因科技有限公司 | 141,285,593 | 33.77% | 1 本次拟参与询价转让的股东为深圳华大基因科技有限公司（以下称华大控 股或出让方）； 出让方拟转让股份总数为 16,732,683 股，占深圳华大基因股份有限公司（以 下简称华大基因或公司）总股本 ...

Core Insights - The article highlights BGI's ambition to transition from being labeled merely as a "gene sequencing factory" to becoming a comprehensive player in the life sciences sector, showcasing its broader strategic vision and innovations in various fields [1][11]. Group 1: Technological Advancements - BGI's flagship product, the DNBSEQ-T7+ ultra-high-throughput sequencer, can process 35,000 whole genomes annually and deliver over 14TB of data within 24 hours, addressing efficiency bottlenecks in large-scale sequencing and providing a cost-effective foundation for downstream applications [3][11]. - The introduction of the spatiotemporal transcriptome FFPE V1.1 product demonstrates BGI's commitment to applying core technologies to solve real-world research and clinical challenges [5]. Group 2: Market Expansion - BGI is shifting its focus from B2B research services to the consumer market, launching several direct-to-consumer (DTC) products, including a rapid alcohol tolerance test and customized probiotics based on gut microbiome data, indicating a strategic move towards the broader health market [6][11]. - The company aims to create a commercial ecosystem through its i99 health management platform and GigaLab smart laboratories, facilitating a closed-loop system from data detection to personalized intervention [6][11]. Group 3: Strategic Initiatives - BGI is exploring strategic "blue ocean" markets in public health and agricultural food sectors, with initiatives like rapid pathogen identification solutions and data-driven medical systems aimed at enhancing public health infrastructure [9][10]. - In agriculture, BGI is promoting sustainable practices such as perennial rice cultivation and soil improvement, alongside implementing DNA technology for food traceability, showcasing its commitment to modernizing agriculture through biotechnology [10]. Group 4: Future Vision - The company is transitioning from being a participant in the industry to becoming a leader, achieving vertical integration across the entire value chain from equipment manufacturing to application development, thereby gaining control over industry standards [11]. - BGI is actively working to democratize advanced genetic technologies, transforming complex scientific concepts into accessible consumer products, which reflects its urgent need to find new growth avenues and the maturation of the genetic technology industry [11][12]. - The integration of AI and data science into BGI's core operations signifies its alignment with global trends in biotechnology and information technology, positioning itself for future advancements in health management [12].

Core Insights - BGI Genomics celebrated its 26th anniversary with a global product launch, emphasizing the theme "Health and Beauty for All" and marking a new phase in China's genomic technology industry [1] Group 1: Product Launch and Innovations - BGI Genomics introduced several key products and solutions, including the SEQALL comprehensive genomic solution and the BGI Smart Medical System, aimed at enhancing public health and personalized health management [1] - The 133111i multi-omics health management model was unveiled, focusing on personalized health strategies rather than traditional one-size-fits-all approaches, integrating various health metrics into a digital life map for individuals [1][2] Group 2: Technological Advancements - The GigaLab Smart Laboratory, described as a "data black factory," automates the entire process from sample handling to result output, ensuring consistent data quality and enabling large-scale implementation [2] - The i99 Smart Health platform supports the 133111i model by providing health insights and personalized plan customization, facilitating a shift from passive healthcare to proactive health management [2] Group 3: Strategic Developments - BGI Genomics has initiated the construction of the "BGI Space Smart Health Center," collaborating with various organizations to establish a strategic presence in key regions of China, including Shenzhen, Wuhan, and Tianjin [3] - The company's evolution from a research institution to a comprehensive technology group reflects the broader development of China's genomic technology sector since its involvement in the Human Genome Project in 1999 [3] Group 4: Vision and Impact - BGI Genomics aims to demonstrate that genomic technology can not only decode life but also transform living standards, highlighting its commitment to advancing health through innovation [4]

Core Insights - BGI Genomics celebrated its 26th anniversary with a global product launch, emphasizing the theme "Health and Beauty for All" and marking a new phase in China's genetic technology industry [1] - The company introduced several key products and solutions, including the SEQALL comprehensive genomic solution and the BGI Smart Medical System, aimed at enhancing public health and personalized health management [1][2] - BGI's Vice President proposed a "Public Health Big Data Era," advocating for a data-driven and intelligent collaborative health system to address traditional public health challenges [1][2] Product and Service Innovations - The 133111i multi-omics health management model was launched, focusing on personalized health strategies rather than traditional one-size-fits-all approaches [1][2] - The GigaLab Smart Laboratory, described as a "data black factory," automates the entire process from sample handling to result output, ensuring consistent data quality and enabling large-scale implementation [2] - The i99 Smart Health platform integrates health insights and personalized plan customization, promoting a shift from "passive healthcare" to "active health management" [2] Strategic Developments - BGI has initiated the construction of the "BGI Space Smart Health Center," collaborating with various organizations to establish a strategic presence in key regions of China, including Shenzhen, Wuhan, and Tianjin [3] - The company's evolution from a research institution to a comprehensive technology group reflects the broader development of China's genetic technology sector since its involvement in the Human Genome Project in 1999 [3][4]

Group 1 - The core message emphasizes the importance of health and wellness, advocating for a lifestyle that includes good nutrition, physical activity, adequate sleep, and positivity [2] - The CEO of BGI Group, Yin Ye, highlights the need for technological innovation to be accessible and affordable, particularly in the context of expensive foreign therapies [2] - There is a belief that as core tools in life sciences become more accessible and the marginal cost of digital health approaches zero, a new norm of health and longevity will emerge [2] Group 2 - BGI Group has signed cooperation agreements with multiple companies, including Gene+ and Berry Technology, to become the first batch of clients for the T7+ system [4] - A collaborative initiative called the "Hundred Thousand Long Read Genome Alliance" has been established, involving BGI and 14 medical and research institutions [5] - BGI is also working with various partners to create a digital health ecosystem that integrates biological intelligence and health services [5] Group 3 - A strategic cooperation agreement has been signed between BGI Group and the management bureau of Hainan Boao Lecheng International Medical Tourism Pilot Zone to enhance collaborative innovation [7] - Yin Ye has been appointed as the "Chief Science Communication Ambassador" for the Lecheng area [7]

证券日报网讯华大基因（300676）9月10日在互动平台回答投资者提问时表示，公司始终高度重视产品 合规化建设，在感染防控领域，基于宏基因组方法学的病原体检测试剂盒资质申报工作在加速推进中。 肿瘤防控领域，用于肠癌防控的DNA甲基化检测和用于宫颈癌防控的HPV分型基因检测已成为惠民检 测项目，大人群民生项目模式已经初见成效。 ...

Core Viewpoint - The company is undergoing a critical business transformation phase, focusing on addressing common pain points in the gene testing and sequencing industry, such as complexity, high costs, and barriers to interpretation and consultation [1] Group 1: Business Transformation - The company is increasing its research and development efforts to enhance automation and intelligence capabilities [1] - The company has a long-term layout in various medical testing fields, including reproductive health, oncology, and infectious disease prevention [1] Group 2: New Technology and Services - The company launched the "i99 Smart Health System" based on its core technology "133111i," which will help extend its business from precision medicine to precision health management [1] - This expansion aims to broaden the company's business boundaries and enhance service value [1]

Core Insights - The report released by Wisdom芽 highlights the increasing presence of Chinese companies in the global innovation landscape, with 11 Chinese firms making it to the "2025 Global Innovation Leaders TOP 100" list [1] - Chinese companies are leading in technology exports, with PCT patent submissions accounting for approximately 47% of the total as of July this year [1] - The report identifies information technology and semiconductors as the dominant sectors, with 17 and 16 companies respectively in the Chinese innovation leaders list [1] - The Beijing-Tianjin-Hebei region shows active R&D, while the Guangdong-Hong Kong-Macau area is recognized for its high-quality technology influence [1] - The global innovation leader landscape is undergoing generational shifts, with new companies driving a quarter of global technological innovation [1] - The semiconductor sector has seen a significant increase, with 13 leading companies entering the global innovation leaders list [1] Company Highlights - The "2025 China Innovation Leaders TOP 100" includes major firms such as Huawei, ZTE, SMIC, Alibaba, BYD, and Mindray, representing the strongest technological capabilities in China [2] - New entrants to the list this year include BGI Genomics, JD.com, Kuaishou Technology, and others, indicating a dynamic shift in the innovation landscape [3] - The report emphasizes the role of these companies as pioneers in advancing China's strategy for technological self-reliance [2]

针对遗传性疾病检测难题，SEQALL全基因组解决方案突破技术盲点，可覆盖神经纤维瘤、Pendred综 合征、血友病等复杂疾病及变异类型，能在孕前、孕期提供风险评估，助力精准防控。 为破解海量测序数据解读难题，华大基因升级AI应用。去年发布的基因检测大模型GeneT已服务241家 机构；此次推出的GeneT Agent作为通用智能体，可完成问诊增强、报告生成等全流程，与临床专家诊 断一致率达98%，效率提升60.7%；iGeneT Pro则为专业人员提供解读支持，二者共同支撑BGI智惠医学 系统。该系统通过"数据聚生态、智能惠场景、云边智协同"，打通健康数据与临床应用，推动基因检测 从专家经验驱动转向数据智能驱动。 朱师达表示，科学探索的每一次进步都在推动公共卫生和个人健康向前迈进，帮助更多人"生得优、老 得慢、病得少、活得长"，让"人人健康"的未来逐步走向现实。(完) 中新网广东新闻9月9日电 (记者 索有为)总部位于深圳的华大集团旗下华大基因，9日推出SEQALL全基 因组综合解决方案、BGI智惠医学系统及SEQALL、GeneT Agent、iGeneT Pro三大核心产品，以全读长 技术与AI推动公共卫 ...

Core Viewpoint - BGI Genomics experienced a stock price decline of 2.02% on September 10, 2023, with a current price of 51.03 CNY per share and a total market capitalization of 21.347 billion CNY [1] Financial Performance - For the first half of 2025, BGI Genomics reported a revenue of 1.631 billion CNY, a year-on-year decrease of 12.82%, and a net profit attributable to shareholders of 5.7782 million CNY, down 68.25% year-on-year [2] - The company has distributed a total of 1.024 billion CNY in dividends since its A-share listing, with 455 million CNY distributed in the last three years [3] Stock Market Activity - As of September 10, 2023, BGI Genomics' stock has increased by 21.59% year-to-date, with a slight increase of 0.10% over the last five trading days, a decrease of 2.33% over the last 20 days, and an increase of 4.19% over the last 60 days [1] - The stock's trading volume on September 10 was 2.23 billion CNY, with a turnover rate of 1.04% [1] Shareholder Structure - As of June 30, 2025, BGI Genomics had 64,300 shareholders, an increase of 3.85% from the previous period, with an average of 6,468 circulating shares per shareholder, a decrease of 3.13% [2] - The top ten circulating shareholders include notable ETFs and funds, with significant increases in holdings for several of them [3]